Zinger Key Points
- Walgreens reported Q1 sales of $39.5 billion, up 7.5% YoY, surpassing the $37.3 billion consensus.
- U.S. Healthcare sales rose to $2.2 billion, with VillageMD up 9%, CareCentrix up 16%, and Shields up 30%. Retail sales fell 6.2% YoY.
- 9 Out of the Last 10 Summers this "Power Pattern" Delivered Winners - Get The Details Now.
On Friday, Walgreens Boots Alliance Inc (NASDAQ: WBA) reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the consensus of $37.28 billion, reflecting sales growth across all segments.
Adjusted operating income was $593 million compared to adjusted operating income of $687 million in the year-ago quarter, reflecting lower U.S. retail sales and lapping prior year sale-leaseback gains, partly offset by cost savings initiatives and growth in the U.S. Healthcare segment.
Adjusted EPS was $0.51, down from $0.66 a year ago, beating the consensus of $0.37, according to data from Benzinga Pro.
Also Read: Walgreens Faces Strategic Challenges, Analysts Are Cautiously Optimistic
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.
Pharmacy sales increased by 10.4%, and comparable pharmacy sales increased by 12.7%, driven by higher branded drug inflation and prescription volume.
Comparable prescriptions increased by 2.3%, and prescriptions excluding immunizations increased by 3.5% compared to a year ago.
Total prescriptions filled in the quarter, including immunizations, increased 1.5% to 316.3 million.
Retail sales decreased 6.2%, and comparable retail sales decreased 4.6% compared with the year-ago quarter, mirroring a weaker cough cold flu season and lower sales in discretionary categories.
The U.S. Healthcare segment's sales were $2.2 billion. VillageMD sales increased 9%, CareCentrix sales increased 16%, and Shields sales rose 30%.
Guidance: Walgreens Boots Alliance maintains fiscal 2025 adjusted EPS guidance of $1.40 – $1.80 versus the consensus of $1.52.
The company expects growth in U.S. Healthcare and International offset by pressure in U.S. Retail Pharmacy largely driven by weaker retail front end performance.
Price Action: WBA stock is up 16.3% at $10.72 during the premarket session at last check Friday.
Read Next:
Image via Shutterstock.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
